Theracos   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Marlborough MA United States (2000)

Organization Overview

First Clinical Trial
2007
NCT00485017
First Marketed Drug
2023
bexagliflozin (Brenzavvy)
First NDA Approval
2023
bexagliflozin (Brenzavvy)
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Theracos | THERACOSBIO | Theracos, Inc. | Theracos Sub, LLC